

genOway announces a 2-year general agreement with the renowned IMM - University of Zurich

Lyon, France - 13 January 2009 - genOway (ALTERNEXT-NYSE:ALGEN) reports a general agreement with the Institute of Medical Microbiology (IMM) - University of Zurich. Thanks to this agreement, researchers of the Institute will benefit from genOway's expertise in transgenesis and from innovative technologies like inducible systems that secure and speed up the creation of sophisticated genetically modified mouse models.

«Technologies developed by genOway will enable us to have access to highly innovative tools and models, which represents a key advantage in our field.» **said Prof. Erik C. Böttger, M.D., Director and Chairman of the Institute of Medical Microbiology.**

«genOway is very proud to collaborate with the Institute of Medical Microbiology. We believe that such collaboration would be highly valuable for both partners as each brings its expertise for a common goal.» **said Alexandre Fraichard, CEO of genOway.**

For more information, please contact:

For business opportunities: Kader Thiam, VP Transgenic Technologies

For press relations: Marie Norbert, communications department

Email: info@genoway.com / Tel : +33 (0)4 37 65 41 00

About the IMM (Institute of Medical Microbiology – Zurich)

The University of Zurich, a member of the League of European Research Universities, provides numerous academic services and research facilities, such as the functional genomics centre (www.fgcz.ethz.ch). The university collaborates with public and private sector organisations, making it an integral part of a national and global network for the acquisition and dissemination of knowledge. The Institute of Medical Microbiology (IMM) at the University of Zurich is involved in research, teaching and diagnostic services (www.imm.uzh.ch). The IMM consists of approx. 125 staff members, 95 of which are financed by the university and the remainder by research grants and outside funding. IMM promotes the continued integration among research areas involving microbiology, molecular genetics, biochemistry and cell biology, creating a highly interdisciplinary environment. The institute is fully equipped with the highest technological standards including cell biology facilities, imaging systems, molecular genetic, biochemistry and biosafety laboratories. **Prof. Dr. Erik C. Böttger**, Chairman and Head of the IMM, has received numerous awards including the prestigious Körber Award for European Science; he is ranked among the world's most cited and influential microbiologists of the past two decades (isihighlycited.com).

About genOway:

genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the reliability and relevancy of in vivo research projects. Focusing its efforts on the mouse and rat, genOway's expertise comprises transgenic technologies such as pronuclear microinjection, knock-out, knock-in, knock-down, point mutation and humanization combined with innovative patented technologies adapted to target validation, in vivo drug screening as well as drug efficacy and safety trials. Collaborations with world leaders (Charles River Laboratories, Invitrogen, Tet systems, etc.) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization. Operating in 22 countries in Europe, North America and Asia, genOway has developed rat and mouse lines for 55 companies and 190 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King's College London, Max Planck Institute) and with pharmaceutical companies (BayerCorp, Boehringer Ingelheim, Johnson & Johnson). For more information consult: www.genoway.com